XRCC6 and hepatoblastoma: To confirm our results in HepG2 cells, we further examined the effects of PARP1 inhibition by DPQ treatment on the PARP1/Ku80/Ku70 complexes and TSPs in another hepatoblastoma cell line, Huh6.